Maryland HB1469 establishes a workgroup to study the definition of "specialty drug" and recommend a new definition.

Maryland HB1469 directs the Maryland Insurance Administration to form a workgroup to study the current definition of "specialty drug." The workgroup will include representatives from various healthcare sectors, such as pharmacy benefits managers, independent pharmacists, carriers, managed care organizations, and hospitals. Their task is to assess the current definition's impact on stakeholders and patients, compare it with federal, state, and international definitions, and propose a new definition that benefits all parties.

Maryland HB1469 establishes a workgroup to study the definition of "specialty drug" and recommend a new definition.

Maryland HB1469 directs the Maryland Insurance Administration to form a workgroup to study the current definition of "specialty drug." The workgroup will include representatives from various healthcare sectors, such as pharmacy benefits managers, independent pharmacists, carriers, managed care organizations, and hospitals. Their task is to assess the current definition's impact on stakeholders and patients, compare it with federal, state, and international definitions, and propose a new definition that benefits all parties.